Integra Lifesciences Hldgs Cp Stock Price, News & Analysis

Integra LifeSciences Holdings Corporation (IART) reported third-quarter 2020 revenues of $370.2 million, down 2.3% year-over-year but up 43.1% sequentially. GAAP earnings per diluted share were $0.38, reversing a loss from the prior year. Adjusted net income increased to $67.7 million, or $0.80 per share. The company maintained a strong financial position with $396 million in cash. However, full-year 2020 guidance remains withdrawn due to COVID-19 uncertainties impacting surgical volumes. Management expects further revenue improvement in Q4, barring significant pandemic setbacks.

Integra LifeSciences (NASDAQ: IART) reported preliminary third quarter revenue of $368 to $370 million, indicating a 2.7% decline year-over-year. This organic revenue decline of 1.8% is a significant recovery from the 32.6% decrease in the second quarter. The results surpassed the company's earlier outlook and showed broad-based sales improvements across its major franchises. Full financial results will be released on October 28, 2020, along with a conference call for further insights.

Integra LifeSciences (NASDAQ: IART) has announced its participation in two upcoming investor conferences in September 2020. Carrie Anderson, the CFO, will present at the Wells Fargo 2020 Virtual Healthcare Conference on September 10 at 9:20 AM ET, followed by CEO Peter Arduini at the Morgan Stanley Virtual Global Healthcare Conference on September 14 at 10:30 AM ET. Both presentations will be webcasted on the company’s investor relations website. Integra is a leader in regenerative technologies and aims to enhance patient care through its comprehensive product portfolio.

Integra LifeSciences Holdings Corporation (IART) reported second-quarter revenues of $258.7 million, down 32.6% year-over-year, mainly due to COVID-19's impact on surgical procedures. The company reported a GAAP loss per diluted share of ($0.00) compared to $0.34 in Q2 2019. Adjusted earnings per diluted share fell to $0.33 from $0.73. Gross margins also declined, with GAAP margins at 59.2%. Despite challenges, revenue showed sequential improvement, and the company ended the quarter with $361 million in cash. Full-year guidance remains withdrawn due to ongoing uncertainties.

Integra LifeSciences Holdings Corporation (Nasdaq:IART) has received FDA clearance for its CUSA® Clarity Ultrasonic Surgical Aspirator System, specifically for neurosurgery. This system is now indicated for the safe and effective resection of tumors, including malignant and benign types, marking a significant advancement in neurosurgical technology. The CUSA system has over 40 years of clinical use and is noted for its ability to enhance surgical outcomes. The launch aligns with Glioblastoma Awareness Day, highlighting the importance of this technology in treating aggressive brain tumors.

Integra LifeSciences (NASDAQ: IART) announced preliminary second quarter 2020 revenue results, estimating revenues between $254 million and $256 million, reflecting a 34% decline from 2019. Despite improving monthly sales due to lifted COVID-19 restrictions, June sales were down approximately 15% from the previous year's second quarter. The company will share full financial results on August 10, 2020, and acknowledges ongoing uncertainty regarding future revenue impacts.

Integra LifeSciences (IART) has announced a leadership change, promoting Michael McBreen to executive vice president and president of Codman Specialty Surgical, effective June 8, 2020. McBreen replaces Dan Reuvers, who is leaving to become CEO of Tactile Systems Technology. McBreen has a strong background with Codman Neurosurgery, having joined Integra through its acquisition from Johnson & Johnson in 2017. Peter Arduini, CEO, praised McBreen's leadership while acknowledging Reuvers' contributions to the company's success in neurosurgery.

Integra LifeSciences Holdings Corporation (NASDAQ: IART) announced its participation in two investor conferences in May 2020. Glenn Coleman, COO, will present at the BofA Securities Virtual Health Care Conference on May 12 at 11:40 am ET. Carrie Anderson, CFO, will present at the UBS Virtual Global Healthcare Conference on May 20, also at 11:40 am ET, with a webcast available on the company’s investor relations site. The company is a leader in regenerative technologies and emphasizes its commitment to providing high-quality solutions for healthcare professionals.

Integra LifeSciences reported Q1 2020 revenues of $354.3 million, down (1.5)% year-over-year, attributed to COVID-19 impacts. GAAP earnings per diluted share fell to $0.11 from $0.38 in Q1 2019. Adjusted earnings were $0.48, compared to $0.65 previously. The company estimates a revenue hit of $20-$25 million due to deferred surgical procedures. Gross margin decreased to 62.3%, and adjusted EBITDA was $75.7 million. Full-year guidance remains withdrawn due to uncertainties from the pandemic.